Application of Animal Models in the Functional Studies of Eph Family Proteins

doi:10.12300/j.issn.1674-5817.2022.010

Abstract

Abstract:

As a receptor tyrosine kinase with the most family members, erythropoietin-producing hepatocyte kinase (Eph) is closely related to the occurrence and development of malignant tumors and displays a wide range of clinical application value. Animal models have played an important role in exploring the biological functions, molecular mechanisms and screening therapeutic targets of Eph family molecules. In this paper, we reviewed the application and latest research progress of xenotransplantation model, immune-related model, and gene modification model in the study of Eph family's functional research, and summarized the advantages and disadvantages of various models, in order to provide a reference for researchers to select appropriate animal models for Eph related research.

Key words: Erythropoietin-producing hepatocyte kinase, Animal models, Application, Advantages and disadvantages

CLC Number:

R-332

Yaohua HU,Jumei ZHAO,Changhong SHI. Application of Animal Models in the Functional Studies of Eph Family Proteins[J]. Laboratory Animal and Comparative Medicine, 2022, 42(4): 351-357. DOI: 10.12300/j.issn.1674-5817.2022.010.

References 49

1	RUDNO-RUDZIŃSKA J, KIELAN W, FREJLICH E, et al. A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers[J]. Chin J Cancer Res, 2017, 29(4):303-312. DOI:10.21147/j.issn.1000-9604.2017.04.03 .
2	O'LEARY D D, WILKINSON D G. Eph receptors and ephrins in neural development[J]. Curr Opin Neurobiol, 1999, 9(1):65-73. DOI:10.1016/s0959-4388(99)80008-7 .
3	ORICCHIO E, NANJANGUD G, WOLFE A L, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma[J]. Cell, 2011, 147(3):554-564. DOI:10.1016/j.cell.2011.09.035 .
4	KUNG A L. Practices and pitfalls of mouse cancer models in drug discovery[J]. Adv Cancer Res, 2006, 96:191-212. DOI:10.1016/S0065-230X(06)96007-2 .
5	STERNER R M, SAKEMURA R, COX M J, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts[J]. Blood, 2019, 133(7):697-709. DOI:10.1182/blood-2018-10-881722 .
6	KOPETZ S, LEMOS R, POWIS G. The promise of patient-derived xenografts: the best laid plans of mice and men[J]. Clin Cancer Res, 2012, 18(19):5160-5162. DOI:10.1158/1078-0432.CCR-12-2408 .
7	LIN J H, ZENG C T, ZHANG J K, et al. EFNA4 promotes cell proliferation and tumor metastasis in hepatocellular carcinoma through a PIK3R2/GSK3β/β-catenin positive feedback loop[J]. Mol Ther Nucleic Acids, 2021, 25:328-341. DOI:10.1016/j.omtn.2021.06.002 .
8	DOPESO H, MATEO-LOZANO S, MAZZOLINI R, et al. The receptor tyrosine kinase EPHB₄ has tumor suppressor activities in intestinal tumorigenesis[J]. Cancer Res, 2009, 69(18):7430-7438. DOI:10.1158/0008-5472.CAN-09-0706 .
9	ASTIN J W, BATSON J, KADIR S, et al. Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells[J]. Nat Cell Biol, 2010, 12(12):1194-1204. DOI:10.1038/ncb2122 .
10	MIAO H, LI D Q, MUKHERJEE A, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt[J]. Cancer Cell, 2009, 16(1):9-20. DOI:10.1016/j.ccr.2009.04.009 .
11	QAZI M A, VORA P, VENUGOPAL C, et al. Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma[J]. Cancer Res, 2018, 78(17):5023-5037. DOI:10.1158/0008-5472.CAN-18-0267 .
12	王洁. 基于肿瘤标本异种移植模型的胃癌转移相关基因研究[D]. 延安: 延安大学, 2020. DOI:10.27438/d.cnki.gyadu.2020.000548 .
	WANG J. Research of metastasis-related genes derived from gastric cancer patient-derived xenograft models[D].Yan'an :Yan'an University, 2020. DOI:10.27438/d.cnki.gyadu.2020.000548 .
13	LV J H, XIA Q Y, WANG J J, et al. EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer[J].Exp Mol Pathol, 2016, 100(3):402-408. DOI:10.1016/j.yexmp.2016.03.011 .
14	SATO S, VASAIKAR S, ESKAROS A, et al. EPHB₂ carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling[J]. JCI Insight, 2019, 4(23): e132447. DOI:10.1172/jci.insight.132447 .
15	LI S, MA Y, XIE C, et al. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression[J]. Oncotarget, 2015, 6(26): 22587-97. DOI:10.18632/oncotarget.4088 .
16	NEUBER C, BELTER B, MEISTER S, et al. Overexpression of receptor tyrosine kinase EphB4 triggers tumor growth and hypoxia in A375 melanoma xenografts: Insights from multitracer small animal imaging experiments[J]. Molecules, 2018, 23(2). DOI:10.3390/molecules23020444 .
17	FESTUCCIA C, GRAVINA G L, GIORGIO C, et al. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice[J]. Oncotarget, 2018, 9(36):24347-24363. DOI:10.18632/oncotarget.25272 .
18	MIAO B C, JI Z Y, TAN L, et al. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma[J]. Cancer Discov, 2015, 5(3):274-287. DOI:10.1158/2159-8290.CD-14-0295 .
19	YANG X K, YANG Y D, TANG S Q, et al. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model[J]. J Pharmacol Sci, 2015, 129(1):65-71. DOI:10.1016/j.jphs.2015.08.009 .
20	LEUNG H W, LEUNG C O N, LAU E Y, et al. EPHB₂ activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma[J]. Cancer Res, 2021, 81(12):3229-3240. DOI:10.1158/0008-5472.can-21-0184 .
21	TOOSI B M, ZAWILY A EL, TRUITT L, et al. EPHB₆ augments both development and drug sensitivity of triple-negative breast cancer tumours[J]. Oncogene, 2018, 37(30):4073-4093. DOI:10.1038/s41388-018-0228-x .
22	ZHANG J L, DU Z Q, PAN S, et al. Overcoming multidrug resistance by codelivery of MDR1-targeting siRNA and doxorubicin using EphA10-mediated pH-sensitive lipoplexes: in vitro and in vivo evaluation[J]. ACS Appl Mater Interfaces, 2018, 10(25):21590-21600. DOI:10.1021/acsami.8b01806 .
23	ZHANG J L, YANG C R, PAN S, et al. Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo [J]. Drug Deliv, 2018, 25(1):723-737. DOI:10.1080/10717544.2018.1446475 .
24	MORILLON Y M 2nd, SABZEVARI A, SCHLOM J, et al. The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents[J]. Anticancer Res, 2020, 40(10):5329-5341. DOI:10.21873/anticanres.14540 .
25	ZUMWALDE N A, GUMPERZ J E. Modeling human antitumor responses in vivo using umbilical cord blood-engrafted mice[J]. Front Immunol, 2018, 9:54. DOI:10.3389/fimmu.2018.00054 .
26	SANMAMED M F, RODRIGUEZ I, SCHALPER K A, et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice[J]. Cancer Res, 2015, 75(17):3466-3478. DOI:10.1158/0008-5472.CAN-14-3510 .
27	PREVOST N, WOULFE D, TANAKA T, et al. Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred[J]. Proc Natl Acad Sci USA, 2002, 99(14):9219-9224. DOI:10.1073/pnas.142053899 .
28	BERROU E, SOUKASEUM C, FAVIER R, et al. A mutation of the human EPHB2 gene leads to a major platelet functional defect[J]. Blood, 2018, 132(19):2067-2077. DOI:10.1182/blood-2018-04-845644 .
29	BRAUN J, HOFFMANN S C, FELDNER A, et al. Endothelial cell ephrinB2-dependent activation of monocytes in arteriosclerosis[J]. Arterioscler Thromb Vasc Biol, 2011, 31(2):297-305. DOI:10.1161/ATVBAHA.110.217646 .
30	ZHOU Q, FACCIPONTE J, JIN M, et al. Humanized NOD-SCID IL2rg^–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies[J]. Cancer Lett, 2014, 344(1):13-19. DOI: 10.1016/j.canlet. 2013.10.015 .
31	ZHANG L, MEISSNER E, CHEN J, et al. Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis[J]. Sci China Life Sci, 2010, 53(2): 195-203.
32	CHIARI R, HAMES G, STROOBANT V, et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class Ⅱ molecules[J]. Cancer Res, 2000, 60(17):4855-4863.
33	TATSUMI T, HERREM C J, OLSON W C, et al. Disease stage variation in CD4⁺ and CD8⁺ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma[J]. Cancer Res, 2003, 63(15):4481-4489.
34	ALVES P M S, FAURE O, GRAFF-DUBOIS S, et al. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes[J]. Cancer Res, 2003, 63(23):8476-8480.
35	HART D N. Dendritic cells: unique leukocyte populations which control the primary immune response[J]. Blood, 1997, 90(9):3245-3287.
36	YAMAGUCHI S, TATSUMI T, TAKEHARA T, et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines[J]. Cancer, 2007, 110(7):1469-1477. DOI:10.1002/cncr.22958 .
37	YAMAGUCHI S, TATSUMI T, TAKEHARA T, et al. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity[J]. Cancer Immunol Immunother, 2008, 57(12):1861-1869. DOI:10.1007/s00262-008-0514-5 .
38	DOTTI G, GOTTSCHALK S, SAVOLDO B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells[J]. Immunol Rev, 2014, 257(1):107-126. DOI:10.1111/imr.12131 .
39	CHOW K K H, NAIK S, KAKARLA S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma[J]. Mol Ther, 2013, 21(3):629-637. DOI:10.1038/mt.2012.210 .
40	LI N, LIU S H, SUN M J, et al. Chimeric antigen receptor-modified T cells redirected to EphA2 for the immunotherapy of non-small cell lung cancer[J]. Transl Oncol, 2018, 11(1):11-17. DOI:10.1016/j.tranon.2017.10.009 .
41	SHI H, YU F, MAO Y T, et al. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma[J]. J Thorac Dis, 2018, 10(5):2779-2788. DOI:10.21037/jtd.2018.04.91 .
42	WANG E N, CESANO A, BUTTERFIELD L H, et al. Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy[J]. J Immunother Cancer, 2020, 8(2): e001619. DOI:10.1136/jitc-2020-001619 .
43	AN Z J, HU Y, BAI Y, et al. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1[J]. Oncoimmunology, 2021, 10(1):1960728. DOI:10.1080/2162402X. 2021.1960728 .
44	KAMOUN W S, DUGAST A S, SUCHY J J, et al. Synergy between EphA2-ILs-DTXp, a novel EphA2-targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models[J]. Mol Cancer Ther, 2020, 19(1):270-281. DOI:10.1158/1535-7163.MCT-19-0414 .
45	YANG W H, CHA J H, XIA W Y, et al. Juxtacrine signaling inhibits antitumor immunity by upregulating PD-L1 expression[J]. Cancer Res, 2018, 78(14):3761-3768. DOI:10.1158/0008-5472.CAN-18-0040 .
46	FAWAL M A, JUNGAS T, DAVY A. Inhibition of DHFR targets the self-renewing potential of brain tumor initiating cells[J]. Cancer Lett, 2021, 503:129-137. DOI:10.1016/j.canlet.2021.01.026 .
47	MATEO-LOZANO S, BAZZOCCO S, RODRIGUES P, et al. Loss of the EPH receptor B6 contributes to colorectal cancer metastasis[J]. Sci Rep, 2017, 7:43702. DOI:10.1038/srep43702 .
48	BHATIA S, HIRSCH K, BAIG N A, et al. Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model[J]. J Hematol Oncol, 2015, 8:105. DOI:10.1186/s13045-015-0202-9 .
49	MOHD-ZIN S W, ABDULLAH N L, ABDULLAH A, et al. Identification of the genomic mutation in Epha4(rb-2J/rb-2J) mice[J]. Genome, 2016, 59(7):439-448. DOI:10.1139/gen-2015-0142 .

[1]	LIU Yayi, JIA Yunfeng, ZUO Yiming, ZHANG Junping, LÜ Shichao. Progress and Evaluation of Animal Model of Heart Qi-Yin Deficiency Syndrome [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 411-421.
[2]	PAN Yicong, JIANG Wenhong, HU Ming, QIN Xiao. Optimization of Surgical Procedure and Efficacy Evaluation of Aortic Calcification Model in Rats with Chronic Kidney Disease [J]. Laboratory Animal and Comparative Medicine, 2025, 45(3): 279-289.
[3]	LIAN Hui, JIANG Yanling, LIU Jia, ZHANG Yuli, XIE Wei, XUE Xiaoou, LI Jian. Construction and Evaluation of a Rat Model of Abnormal Uterine Bleeding [J]. Laboratory Animal and Comparative Medicine, 2025, 45(2): 130-146.
[4]	YANG Jiahao, DING Chunlei, QIAN Fenghua, SUN Qi, JIANG Xusheng, CHEN Wen, SHEN Mengwen. Research Progress on Animal Models of Sepsis-Related Organ Injury [J]. Laboratory Animal and Comparative Medicine, 2024, 44(6): 636-644.
[5]	HUANG Dongyan, WU Jianhui. Establishment Methods and Application Evaluation of Animal Models in Reproductive Toxicology Research [J]. Laboratory Animal and Comparative Medicine, 2024, 44(5): 550-559.
[6]	ZHENG Yiqing, DENG Yasheng, FAN Yanping, LIANG Tianwei, HUANG Hui, LIU Yonghui, NI Zhaobing, LIN Jiang. Application Analysis of Animal Models for Pelvic Inflammatory Disease Based on Data Mining [J]. Laboratory Animal and Comparative Medicine, 2024, 44(4): 405-418.
[7]	WU Yue, LI Lu, ZHANG Yang, WANG Jue, FENG Tingting, LI Yitong, WANG Kai, KONG Qi. Integrative Analysis of Omics Data in Animal Models of Coronavirus Infection [J]. Laboratory Animal and Comparative Medicine, 2024, 44(4): 357-373.
[8]	WU Xiansheng, HUANG Wei, LIANG Yongfen, DENG Hui, ZHAI Yonghuan, YANG Jiajun, HUANG Ganquan, WANG Gang. Analysis of Breeding and Application Data for Laboratory Cats [J]. Laboratory Animal and Comparative Medicine, 2024, 44(4): 428-435.
[9]	Committee of Experts on Medical Animal Experiments, Chinese Research Hospital Association. Guidelines for the Selection of Animal Models and Preclinical Drug Trials for Spontaneous Intracerebral Hemorrhage (2024 Edition) [J]. Laboratory Animal and Comparative Medicine, 2024, 44(1): 3-30.
[10]	Shuwu XIE, Ruling SHEN, Jinxing LIN, Chun FAN. Progress in Establishment and Application of Laboratory Animal Models Related to Development of Male Infertility Drugs [J]. Laboratory Animal and Comparative Medicine, 2023, 43(5): 504-511.
[11]	Rui ZHANG, Meiyu LÜ, Jianjun ZHANG, Jinlian LIU, Yan CHEN, Zhiqiang HUANG, Yao LIU, Lanhua ZHOU. Research Progress on Establishing and Evaluation of Acne Animal Models [J]. Laboratory Animal and Comparative Medicine, 2023, 43(4): 398-405.
[12]	Jiahui YU, Qian GONG, Lenan ZHUANG. Animal Models of Pulmonary Arterial Hypertension and Their Application in Drug Research [J]. Laboratory Animal and Comparative Medicine, 2023, 43(4): 381-397.
[13]	Ling HU, Zhibin HU, Yunqing HU, Yuqiang DING. Overview of Studies in Animal Models of Schizophrenia [J]. Laboratory Animal and Comparative Medicine, 2023, 43(2): 145-155.
[14]	Feng WEI, Weiwei CHENG, Yafu YIN. Characteristics and Application of Transgenic Mouse Models in Alzheimer's Disease [J]. Laboratory Animal and Comparative Medicine, 2022, 42(5): 432-439.
[15]	Zhejin SHENG, Limei LI. Research Progress in Animal Model of Alzheimer's Disease [J]. Laboratory Animal and Comparative Medicine, 2022, 42(4): 342-350.